Thursday, January 3, 2013- Are Short-Sellers Onto Something at Peregrine?at Motley Fool (Thu, Jan 3)
- Labrys Bioscience, founded by Corey Goodman, snags Pfizer migraine drug, $31 millionat bizjournals.com (Thu, Jan 3)
- [video] Morningstar's Top Fund Managersat CNBC (Thu, Jan 3)
- What Will Be the Top Dog in 2013?Zacks (Thu, Jan 3)
- What You Need to Know About Big Pharmaat Motley Fool (Thu, Jan 3)
- Chevron Announces New Reserves and 3 Dow Movers Seeing Actionat Wall St. Cheat Sheet (Thu, Jan 3)
- Ex-SAC Manager Martoma Pleads Not Guilty to Insider Tradingat Bloomberg (Thu, Jan 3)
- Repligen forms partnership on spinal muscle drugAP (Thu, Jan 3)
- Schizo-Well Fargo? Bank Has Two Market Gurus – Two Very Different 2013 PredictionsYCharts (Thu, Jan 3)
- 2 Risks That Could Crush MannKind in 2013at Motley Fool (Thu, Jan 3)
- Inside The Pricing Of A $300,000-A-Year Drugat Forbes (Thu, Jan 3)
- 2012 job cuts lowest since 1997, says Challenger, Grayat bizjournals.com (Thu, Jan 3)
- S&P 500 Index Gains the Most Since 2009 -- Fiscal Cliff Likely to Be AvoidedMarketwired (Thu, Jan 3)
- The Future Arrives for Abbott Labsat Motley Fool (Thu, Jan 3)
- 5 Value Stocks For 2013at Seeking Alpha (Thu, Jan 3)
- Repligen enters into licensing agreement with Pfizer for SMA programat theflyonthewall.com (Thu, Jan 3)
Wednesday, January 2, 2013- Do Lilly's Financials Make the Grade?at Motley Fool (Wed, Jan 2)
- Pfizer Moves Up In Market Cap Rank, Passing Procter & Gamble Co.at Forbes (Wed, Jan 2)
- SAC Sued by Elan Investors Over Alleged Insider Tradesat Bloomberg (Wed, Jan 2)
- A Bio-Pharmaceutical Trailblazer Up 77% in 2012at Motley Fool (Wed, Jan 2)
- Are These 3 Stocks Worthy Of Your Portfolio?at Motley Fool (Wed, Jan 2)
- National Science Foundation gives $2.7M to Biomanufacturing Center and Collaborativeat bizjournals.com (Wed, Jan 2)
- Pfizer Wins FDA Approval and 4 Dow Movers Sparking Chatterat Wall St. Cheat Sheet (Wed, Jan 2)
- These Dow Dividend Stocks Are Celebratingat Motley Fool (Wed, Jan 2)
- UPDATE: With Multimedia: U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial FibrillationBusiness Wire (Wed, Jan 2)
Add PFE News to My Yahoo!   | |
|
0.30(1.02%) 4:01PM EDT|After Hours
:
29.18